Clinical Trial Search

Primary: Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — 10; 19; 9; 0…

Primary: Progression-free Survival (PFS) — 7.5; 5.5 months

Primary: Percentage of Participants Who Experienced At Least 2-Fold Increase in Expression of IL-12 Protein in the Tumor Tissue After Intratumoral (IT) pIL-12 Injections and In…

Primary: Response Rate — 0; 0; 26; 11 Participants

Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg

Primary: Objective Response Rate (ORR) — 49.1 Percentage of participants

Primary: Objective Response Rate (ORR) — 52.3 percentage of participants

Primary: MLN01283 Maximum Tolerated Dose (MTD) [Phase I] — 3 mg

Primary: Best Response — 1; 1; 0; 0 Participants

Primary: Maximum Tolerated Dose (MTD) — 300 mg

Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants

Primary: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation…

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…

Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months